Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM15 post-trial access study of elranatamab in multiple myeloma
jRCT2041230141Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Primary endpoints: Incidence of nonserious adverse events leading to permanent discontinuation and Incidence of serious adverse events. Started Jul 2025; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2041230141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230141.